Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Cerebral Aneurysm Management Market Snapshot

The global cerebral aneurysm management market is expected to garner a market value of US$ 1.56 Billion in 2023 and is expected to accumulate a market value of US$ 2.98 Billion by registering a CAGR of 6.7% in the forecast period 2023 to 2033. Growth of the cerebral aneurysm management market can be attributed to rise in geriatric population and availability of different medications to treat the ailment. The market for cerebral aneurysm management registered a CAGR of 4% in the historical period 2018 to 2022

Cerebral aneurysm management refers to the diagnosis and treatment of cerebral aneurysms, which are weak spots in the blood vessels of the brain that can bulge or burst, leading to bleeding in the brain (also known as a subarachnoid hemorrhage). Cerebral aneurysm management typically involves a combination of medical and surgical techniques to diagnose, treat, and prevent the occurrence of aneurysms. The goals of management include reducing the risk of aneurysm rupture, preventing further bleeding if an aneurysm has ruptured, and minimizing any resulting neurological damage.

Report Attribute Details
Expected Market Value (2023) US$ 1.56 Billion
Anticipated Forecast Value (2033) US$ 2.98 Billion
Projected Growth Rate (2023 to 2033) 6.7% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Cerebral Aneurysm Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for cerebral aneurysm management reflected a value of 4% during the historical period, 2018 to 2022.

Diagnostic techniques for cerebral aneurysms include imaging tests such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, and angiograms. Treatment options may include minimally invasive procedures such as endovascular coiling or stenting, or open surgical procedures such as clipping.

Cerebral aneurysm management is a rapidly evolving field, with new diagnostic and therapeutic techniques being developed and refined to improve patient outcomes. Effective management of cerebral aneurysms requires close collaboration between specialists in neurosurgery, neurology, and interventional radiology.

Thus, the market for cerebral aneurysm management is expected to register a CAGR of 6.7% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Cerebral Aneurysm Management Market?

Availability of various treatments driving the growth of cerebral aneurysm management market

The incidence of cerebral aneurysms is increasing worldwide, which is driving demand for effective management and treatment options. The development of minimally invasive techniques and new devices for the treatment of cerebral aneurysms is driving growth in the market.

Surgical Clipping: Involves the placement of a small metal clip at the base of the aneurysm to block blood flow and prevent rupture.

Endovascular Coiling: A minimally invasive procedure where a coil is inserted into the aneurysm through a catheter to fill the sac and prevent blood flow.

Flow Diverter Stenting: A newer endovascular technique where a stent is placed across the neck of the aneurysm to redirect blood flow and shrink the aneurysm.

Observation: For smaller or stable aneurysms that do not show symptoms, regular imaging and monitoring may be recommended to track any changes.

Aging population and government initiatives increasing demand for treatment of cerebral aneurysm

The aging population is more susceptible to cerebral aneurysms, which is leading to increased demand for management and treatment options. Increased public awareness about the symptoms and consequences of cerebral aneurysms is driving demand for early diagnosis and treatment.

Governments around the world are investing in healthcare infrastructure and encouraging innovation in medical technologies, which is driving growth in the market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Cerebral Aneurysm Management Market

High cost along with restricted reimbursement creating obstacles for market growth

The cost of treatment for cerebral aneurysms can be high, which can be a barrier for some patients and healthcare systems. There is a shortage of skilled healthcare professionals trained in the diagnosis and treatment of cerebral aneurysms, which can limit access to care.

Reimbursement for cerebral aneurysm treatments can be limited in some countries, which can impact market growth. Strict regulatory requirements for the approval of new devices and treatments can slow market growth and limit access to innovative solutions. The cerebral aneurysm management market faces competition from alternative treatments, such as surgical clipping and endovascular coiling, which can limit market growth.

Region Wise Insights

Prevalence of Cerebral Aneurysm in North America Creating Lucrative Opportunities for Treatment?

Advanced healthcare infrastructure increasing treatment options for cerebral aneurysm

North America has a high incidence of cerebral aneurysms, which is driving demand for effective management and treatment options. Moreover, it has a technologically advanced healthcare infrastructure, with access to cutting-edge treatments and technologies for the management of cerebral aneurysms.

North America is home to some of the leading companies in the cerebral aneurysm management market, which is driving innovation and growth in the market. Reimbursement policies for cerebral aneurysm treatments are favorable in North America, which is driving demand for treatments and contributing to market growth. In addition, the region has high levels of healthcare spending, which is supporting the growth of the cerebral aneurysm management market. Thus, North America is expected to possess 45% market share for cerebral aneurysm management market in 2023.

Increase in Healthcare Spending Driving Growth of Cerebral Aneurysm Management Market in Europe?

Key market players innovating treatment methods for cerebral aneurysm in Europe

The Europe cerebral aneurysm management market refers to the market for medical devices, procedures, and treatments for the diagnosis and treatment of cerebral aneurysms in the European region. This market is expected to grow due to increasing incidence of cerebral aneurysms and advancements in technology. Major players in the market include Johnson & Johnson, Stryker, Medtronic, Terumo, and others. The market growth may be hindered by factors such as high costs of treatments and a lack of awareness about the condition.

The market for cerebral aneurysm management in Europe is growing due to a combination of factors such as increasing incidence, advancements in technology, growing geriatric population, increasing healthcare spending, and increased awareness about the condition. Thus, Europe is expected to possess 37% market share for cerebral aneurysm management market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Availability of Medication Making Hospital Pharmacies a Favorbale Option for Treating Cerebral Aneurysm?

Favorable reimbursement policies are making hospital pharmacies a viable option for treatment

On the basis of distribution channel, cerebral aneurysm management market is categorized into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

The hospital pharmacy segment is expected to dominate the market, driven by the availability of various treatments and diagnostic options for cerebral aneurysm. The presence of healthcare professionals as well as favorable reimbursement policies, further solidify hospital pharmacies as a preferred choice for treatment.

The growth is also encouraged by government initiatives that support the treatment of cerebral aneurysm in hospital pharmacies. The market share of hospitals for cerebral aneurysm is expected to reach 40% in 2023.

Market Competition

Key players in the cerebral aneurysm management market are Biogen, Pfizer Inc, Hoffmann-La Roche Ltd, Merck Sharp & Dohme Corp, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Corporation, UCB S.A., Acadia Pharmaceuticals Inc, Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation

  • Novartis AG, a key player in the cerebral aneurysm management market is emphasizing on investing in extensive research to develop medications that can alleviate the symptoms associated with cerebral aneurysm.
  • Acadia Pharmaceuticals Inc, another key player in the cerebral aneurysm management market is working with healthcare professionals to develop medications to treat immediate after effects of cerebral aneurysm.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.56 Billion
Market Value in 2033 US$ 2.98 Billion
Growth Rate CAGR of 6.7% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa
Key Companies Profiled
  • Biogen
  • Pfizer Inc.
  • Hoffmann-La Roche Ltd
  • Merck Sharp & Dohme Corp
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Orion Corporation
  • UCB S.A.
  • Acadia Pharmaceuticals Inc.
  • Lundbeck A/S
  • Mitsubishi Tanabe Pharma Corporation
Customization Available Upon Request

Key Segments Profiled in the Cerebral Aneurysm Management Market Survey

Drug Class:

  • Antihypertensives
  • Antiepileptics
  • Analgesics
  • Antiemetics
  • Antacids

Route of Administration:

  • Oral
  • Injectable
  • Transdermal

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

How big is the market in 2023?

The market is expected to be valued at US$ 1.5 billion in 2023.

Who are the key market players?

Biogen, Pfizer Inc., and Hoffmann-La Roche Ltd. are key market players.

How is the historical performance of the market?

From 2018 to 2022, the market registered a CAGR of 4.0%.

What opportunities await the market players?

Availability of various treatments to boost the market prospects.

What is the growth forecast for Market?

The market is forecast to register a CAGR of 6.7% through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Antihypertensives

        5.3.2. Antiepileptics

        5.3.3. Analgesics

        5.3.4. Antiemetics

        5.3.5. Antacids

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

        6.3.3. Transdermal

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online Pharmacy

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Biogen

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Pfizer Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. F. Hoffmann-La Roche Ltd

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Merck Sharp & Dohme Corp.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Novartis AG

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Sanofi

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Teva Pharmaceutical Industries Ltd.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Orion Corporation.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. UCB S.A.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Acadia Pharmaceuticals Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. H. Lundbeck A/S

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. Mitsubishi Tanabe Pharma Corporation

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Dry Eye Syndrome Treatment Market

Published : October 2023

Healthcare

Short Sleep Syndrome Treatment Market

Published : March 2023

Healthcare

Myelodysplastic Syndrome Treatment Market

Published : July 2022

Explore Healthcare Insights

View Reports

Cerebral Aneurysm Management Market